Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211876 | 0.86 | GLP1R (0.42) | MAPTCYP1A2CYP2D6KMT2APOLB | |
| SCHEMBL31451855 | 0.84 | LMNA (0.42) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL3175111 | 0.82 | CRHBP (0.50) | MAPTCYP1A2CYP2D6KMT2APOLB | |
| SCHEMBL23773650 | 0.81 | PIK3CA (0.42) | MAPTCYP1A2CYP2D6KMT2APIK3CB | |
| SCHEMBL22050882 | 0.81 | PIK3CA (0.42) | MAPTCYP1A2CYP2D6KMT2APIK3CB | |
| SCHEMBL26380932 | 0.80 | PDCD1 (0.54) | ATRATRIP | |
| SCHEMBL22098492 | 0.79 | AKT1 (0.41) | MAPTCYP1A2CYP2D6KMT2APIK3CB | |
| SCHEMBL4114316 | 0.77 | PIK3CA (0.52) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL30353341 | 0.76 | CYP1A2 (0.66) | MAPTCYP1A2CYP2D6KMT2APOLB | |
| SCHEMBL913131 | 0.76 | CYP1A2 (0.66) | MAPTCYP1A2CYP2D6KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312336-B2 | Inhibitors of RAF kinases | Pierre Fabre Médicament (FR) | 2025-05-27 | — | — | US | disclosed |
| CN-114845711-B | Inhibitors of RAF kinase | 皮埃尔法布雷医药公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| EP-4048259-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114845711-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20210300904-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-09-30 | — | — | US | disclosed |
| US-20210300904-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-09-30 | — | — | US | disclosed |
| WO-2021163727-A1 | PIKFYVE KINASE INHIBITORS | AcuraStem Incorporated (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021081375-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| CN-101790525-A | pharmaceutical compounds | HOFFMANN LA ROCHE | 2010-07-28 | — | — | CN | disclosed |
| CN-101765597-A | Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | disclosed |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2150546-A2 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. Hoffmann-Roche AG (CH) | 2010-02-10 | — | — | EP | disclosed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125839-A2 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125839-A2 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIP5K1C | MAPT 1501/4885CYP1A2 4578/4885CYP2D6 4735/4885 |
| US-20210300904-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIK3CA, PIP5K1B, PIK3CD | MAPT 2913/4885CYP1A2 1413/4885CYP2D6 1525/4885 |
| US-12312336-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.